重组人粒细胞刺激因子治疗化疗所致Ⅳ度粒细胞减少最佳给药剂量的回顾性研究  

Retrospective Analysis of the Optimal Dose of rhG-CSF Used in the Patients with Ⅳ-degree Leukopenia Caused by Chemotherapy

作　　者：蒋婷[1] 袁明勇[1] 郑玲利[1] 李燕[1] 曾佳怡 Jiang Ting;Yuan Mingyong;Zheng Lingli;Li Yan;Zeng Jiayi(The First Affiliated Hospital of Chengdu Medical College,Chengdu 610500,China;Chengdu Medical College)

机构地区：[1]成都医学院第一附属医院

出　　处：《中国药师》2020年第1期101-103,共3页China Pharmacist

基　　金：成都医学院第一附属医院院级课题项目(编号:CYFY15DL-01)

摘　　要：目的:通过回顾性研究探讨重组人粒细胞刺激因子(rhG-CSF)治疗化疗所致Ⅳ度粒细胞减少的最佳给药剂量,为临床用药提供参考。方法:收集2017年1月~2019年1月我院化疗同时出现Ⅳ度粒细胞减少的病例,比较不同给药剂量下rhG-CSF治疗的疗效、安全性,并进行药物经济学评价。结果:共纳入38例患者。rhG-CSF低、高剂量组和变化剂量组的短期临床有效率分别为60.0%,83.3%,75.0%,不良反应发生率分别为0,8.33%,5.25%,差异均无统计学意义(P>0.05)。低、高剂量组和变化剂量组的成本分别为1424.06,792.50,887.62元,差异有统计学意义(P<0.05)。结论:综合药物的有效性、安全性和经济性考虑,高剂量rhG-CSF是治疗化疗后Ⅳ度粒细胞减少的最佳给药剂量。Objective:To retrospectively evaluate the optimal dose of rhG-CSF forⅣ-degree leukopenia after chemotherapy to provide reference for later clinical medication.Methods:A retrospective analysis was carried out through obtaining the cases received chemotherapy and complicated withⅣ-degree leulocytopenia from HIS system of our hospital between January 2017 and January 2019,and the efficacy,safety and cost-effectiveness at different doses of rhG-CSF were compared to determine the optimal dose of rhG-CSF in such patients.Results:A total of 38 patients were included for the analysis,and the results showed that the short-term clinical efficacy of low-dose,high-dose and variable-dose groups was 60.0%,83.3%and 75.0%,respectively.The incidence of adverse reactions was 0,8.33%and 5.25%,respectively.The differences were not statistically significant(P>0.05);the cost of low-dose,high-dose and variable-dose groups was 1424.06 yuan,792.50 yuan and 887.62 yuan,respectively,and the difference was statistically significant(P<0.05).Conclusion:Considering the effectiveness,safety and economy of drug,high-dose rhG-CSF is optimal for the treatment ofⅣ-degree leulocytopenia after chemotherapy.

关 键 词：重组人粒细胞刺激因子 化疗 Ⅳ度粒细胞减少 最佳给药剂量 回顾性研究 

分 类 号：R973.4[医药卫生—药品]